Amber Stephens, APRN
Family · Portsmouth, OHNPI 1801259395
Payments from drug & device makers
Across 547 payments — averaging $14.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- Lilly USA, LLC$1K
- Pfizer$903
- AstraZeneca$593
- Amgen$427
- plus $3K from 27 others
What the payments were for
- Food & beverage$8,115100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 92 | $1,304 |
| AbbVie | 74 | $1,103 |
| Lilly USA, LLC | 83 | $1,074 |
| Pfizer | 76 | $903 |
| AstraZeneca | 19 | $593 |
| Amgen | 28 | $427 |
| Boehringer Ingelheim | 28 | $387 |
| Johnson & Johnson | 21 | $261 |
| Bayer | 12 | $237 |
| Abbott | 12 | $212 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $179 |
| Exact Sciences | 10 | $173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $169 |
| Astellas Pharma US Inc | 11 | $153 |
| Dexcom, Inc. | 8 | $145 |
| GSK | 10 | $138 |
| Otsuka America Pharmaceutical, Inc. | 6 | $109 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $93 |
| Collegium Pharmaceutical, Inc. | 5 | $75 |
| Biohaven Pharmaceuticals, Inc. | 5 | $75 |
| Lundbeck LLC | 3 | $46 |
| Amarin Pharma, Inc. | 3 | $39 |
| Kyowa Kirin, Inc. | 2 | $31 |
| Merck | 2 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| Abiomed | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Edwards Lifesciences | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,115 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 173 | $138,643 |
| OzempicSemaglutide | 107 | $133,338 |
| JardianceEmpagliflozin | 117 | $112,706 |
| MounjaroTirzepatide | 64 | $88,365 |
| JanuviaSitagliptin Phosphate | 67 | $66,773 |
| XareltoRivaroxaban | 61 | $59,085 |
| FarxigaDapagliflozin Propanediol | 53 | $54,428 |
| EliquisApixaban | 67 | $41,584 |
| RybelsusSemaglutide | 26 | $28,928 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $21,106 |
| MyrbetriqMirabegron | 35 | $20,793 |
| EntrestoSacubitril/Valsartan | 11 | $19,366 |
| Spiriva RespimatTiotropium Bromide | 29 | $17,397 |
| TradjentaLinagliptin | 19 | $14,994 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $12,063 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,304 | $162,266133 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $138 | $159,748204 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $387 | $145,097165 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,074 | $98,66575 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $593 | $71,62493 claims |
| MerckJanuvia | $29 | $66,77367 claims |
| Johnson & JohnsonXarelto | $261 | $59,08561 claims |
| PfizerEliquis | $903 | $41,58467 claims |
| Astellas Pharma US IncMyrbetriq | $153 | $20,79335 claims |
| NovartisEntresto | $12 | $19,36611 claims |
| AbbVieLinzess | $1,103 | $11,36413 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $169 | $9,14720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Portsmouth
- Thea FloydPortsmouth$23K
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.